This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Strict guidelines from the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) require marketers to ensure transparency and accuracy in all communications. FDA Guidelines and Promotional Review Committees Understanding FDA regulations is critical for all pharma marketing professionals.
Cybersecurity challenges As per a Healthcare Information and Management Systems Society (HIMSS) 2022 survey, there is a need for greater awareness on Health Insurance Portability and Accountability Act (HIPAA) and data privacy along with other measures. Cybersecurity is necessary for biosecurity.”
But as powerful as RTB is, pharma brands must navigate strict regulatory challenges to ensure compliance with FDA and GDPR guidelines. HIPAA and Patient Privacy Concerns RTB relies on user data for targeting, but in the pharma space, this raises serious privacy concerns. HIPAA, GDPR, and FDA regulations must be followed strictly.
They save on purchasing thousands of participant devices and the costs associated with connectivity, insurance, or replacement. Both the EMA and FDA have released draft guidance on the issue and are currently soliciting feedback. Potential regulatory compliance: Regulators recently began recognizing the power of utilizing BYOD devices.
Given the public health emergency, health authorities offered greater flexibilities in the use of digital health platforms and technologies such as: Enhanced HIPAA (Health Insurance Portability and Accountability Act of 1996) flexibilities in the use of telemedicine services 3.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content